Neuren Pharmaceuticals Ltd has released a press release.
Acadia confirms plan to request CHMP re-examination
Earlier from Neuren Pharmaceuticals
- 2025 royalty income A$65m, profit after tax A$30m
- Appendix 4E and 2025 full year accounts
- Acadia reports DAYBUE net sales for 2025 and 2026 guidance
- Pause in Trading